It isn't a cheap buy, but given its strong growth prospects, a premium is justifiable. Lilly could obtain approval for a weight loss pill that would unlock even more growth. Investors should never ...

Learn More » For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45 ...

It might be a small world, but big changes are in store for guests of Disneyland’s Main Street U.S.A. and its "It’s A Small World" attraction. The resort is celebrating its 70th anniversary ...

The mosque in Altadena, which served a tight-knit Muslim community for 42 years, burned to the ground in one of the Los ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

Scott Schau retired from his work as police officer and began driving buses for the school district. Since then Schau has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology ...

2-Year U.S. Treasury Note Continuous Contract $102.871 0.121 0.12% 5-Year U.S. Treasury Note Continuous Contract $106.758 0.281 0.26% 10-Year U.S. Treasury Note Continuous Contract $109.578 0.406 ...